Home > Dermatology > AAD 2019 > JAK Inhibitors: A New Frontier in Dermatology > JAK inhibitors: a new therapeutic tool for dermatologists

JAK inhibitors: a new therapeutic tool for dermatologists

Presented By
Prof. Brett King, Yale School of Medicine, USA
Conference
AAD 2019

JAK inhibitors are a versatile novel drug class that will play a role in different dermatological indications because they block numerous cytokines that play a key role in the pathogenesis of different dermatologic conditions.

"The therapeutic tools of a dermatologist moved from less targeted therapies such as corticosteroids to more target therapies such as TNF-α blockers or cytokine blockers," explained Prof. Brett King (Yale School of Medicine, USA) [1]. The Janus kinase (JAK) family is composed of 4 members: JAK 1,2,3, and tyrosine kinase 2 (TYK2). They play a key role in growth, development, and differentiation [2]. More than 50 cytokines use the JAK-signal transducer and activator of transcription (STAT) pathway. JAK-STAT pathways are involved in signal transduction of many cytokines such as interferon-gamma (IFNγ), IFN-α, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, IL-5, IL-6, IL-12, IL-13, and IL-23 [3].

JAK-inhibitors are currently registered...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on